Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NEVANAC vs BONTRIL PDM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis and thereby suppressing ocular inflammation and pain.
Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the release of norepinephrine and dopamine in the hypothalamus, reducing food intake. Topiramate is a sulfamate-substituted monosaccharide that enhances GABAergic activity and inhibits glutamatergic neurotransmission via AMPA/kainate receptors, leading to appetite suppression and increased energy expenditure.
Treatment of pain and inflammation associated with cataract surgery,Reduction of risk of macular edema following cataract surgery
FDA-approved: Chronic weight management (BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity) as an adjunct to a reduced-calorie diet and increased physical activity.,Off-label: None widely recognized.
One drop of 0.1% ophthalmic suspension instilled into the affected eye(s) three times daily.
Oral: 5-10 mg once daily in the morning; maximum 20 mg/day. Oral disintegrating tablet: 5-10 mg once daily.
The terminal elimination half-life of nepafenac is approximately 12.5 hours in plasma, while its active metabolite amfenac has a half-life of about 24 hours. This supports twice-daily dosing.
Terminal elimination half-life is 12-15 hours in adults, prolonged to 20-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Nepafenac is metabolized via ocular tissues to amfenac, the active metabolite. Systemic metabolism primarily involves hepatic conjugation and oxidation.
Phentermine: primarily renal excretion (unchanged). Topiramate: metabolized by CYP3A4 (minor), but ~70% excreted unchanged in urine. Also undergoes hydrolysis and glucuronidation.
Nepafenac is extensively metabolized, primarily via hydrolysis to amfenac. Renal excretion accounts for approximately 85% of the administered dose, with about 13% excreted as unchanged nepafenac and amfenac in urine. Fecal elimination is minimal.
Renal: ~70% (unchanged), Fecal: ~30% (biliary excretion of metabolites).
Nepafenac is approximately 98% bound to plasma proteins, primarily albumin.
98% bound to albumin.
The apparent volume of distribution (Vd/F) is approximately 0.6 L/kg (range 0.5-0.7 L/kg), suggesting distribution into total body water and some tissue binding.
0.25-0.35 L/kg, indicating distribution primarily in extracellular fluid.
Ophthalmic: Systemic bioavailability after topical ocular administration is very low (approximately 0.1-1% of the dose), but sufficient for local ocular effects. Oral bioavailability is not clinically relevant as drug is only used ophthalmically.
Oral: 65-75% (first-pass metabolism); IM: 85-95%.
No dose adjustment required in renal impairment; systemic exposure is minimal due to topical administration.
GFR >30 m L/min: No adjustment. GFR 10-30 m L/min: Use with caution, reduce dose by 50%. GFR <10 m L/min: Contraindicated.
No dose adjustment required in hepatic impairment; systemic exposure is minimal.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use.
Safety and efficacy in pediatric patients have not been established; use is not recommended.
Children 6-12 years: 2.5-5 mg once daily; maximum 10 mg/day. Children >12 years: Same as adult dosing.
No specific dose adjustment; dosing is identical to standard adult dosing.
Initiate at 2.5 mg once daily; may increase to 5 mg if needed. Use with caution due to increased sensitivity.
No FDA black box warning.
No black box warning for the combination product. However, topiramate is associated with an increased risk of acute myopia and secondary angle closure glaucoma, and teratogenicity (cleft lip/palate with first-trimester exposure).
Increased bleeding time due to antiplatelet effect,Delayed healing or corneal adverse events including keratitis and corneal perforation,Cross-sensitivity with aspirin or other NSAIDs,Use with caution in patients with bleeding diatheses or concurrent anticoagulants
Acute myopia and angle-closure glaucoma (topiramate); discontinue if symptoms occur.,Oligohidrosis and hyperthermia (topiramate), especially in pediatric use.,Fetal toxicity (topiramate): increased risk of oral clefts; contraception required for females of reproductive potential.,Suicidal behavior or ideation (topiramate).,Metabolic acidosis (topiramate): monitor serum bicarbonate.,Increase in heart rate (phentermine): use with caution in patients with cardiac disease.,Pulmonary hypertension (phentermine): rare but serious.,Dependence and abuse potential (phentermine, Schedule IV controlled substance).,Glaucoma angle closure risk.,Kidney stones (topiramate): hydrate to prevent.,Cognitive/neuropsychiatric effects (topiramate): difficulty with memory, concentration, or language.
Hypersensitivity to nepafenac or any component of the formulation,History of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs
Glaucoma (angle-closure), especially with topiramate component.,Hyperthyroidism (phentermine).,Patients with a history of drug abuse (phentermine).,MAO inhibitor use within 14 days (phentermine).,Pregnancy (topiramate is teratogenic).,Breastfeeding (safety not established).,Known hypersensitivity to phentermine or topiramate.,Cardiovascular disease including arrhythmias, coronary artery disease, or uncontrolled hypertension (phentermine).,Concomitant use of other central nervous system stimulants.
No clinically significant food interactions have been identified with ophthalmic nevanac. Systemic absorption is minimal, so dietary restrictions are not required.
Avoid alcohol and caffeine-containing products. High-fat meals may delay absorption. No other specific food restrictions, but follow a reduced-calorie diet as advised by your healthcare provider.
Nepafenac is an NSAID. First trimester: limited human data, but NSAIDs as a class are associated with increased risk of spontaneous abortion and cardiac defects. Second trimester: generally considered lower risk for teratogenicity, but avoid if possible. Third trimester: increased risk of premature closure of the ductus arteriosus, oligohydramnios, and fetal renal impairment. Ophthalmic use results in minimal systemic absorption, but theoretical risks remain. Use only if clearly needed.
First trimester: Category X. Contraindicated due to documented teratogenicity (neural tube defects, craniofacial malformations). Second/third trimester: Avoid due to risk of fetal hemorrhage and premature closure of ductus arteriosus.
No data on nepafenac in breast milk. Ophthalmic administration yields negligible systemic concentrations. M/P ratio not determined. Considered likely compatible with breastfeeding due to minimal absorption, but caution advised.
Excreted into breast milk with M/P ratio of 0.8. Contraindicated during breastfeeding due to risk of infant toxicity (renal impairment, bleeding).
No dose adjustments are typically required due to ophthalmic administration; systemic exposure is negligible. However, avoid use in third trimester unless potential benefit outweighs risk. No pharmacokinetic changes in pregnancy necessitate dose adjustment for topical ophthalmic formulation.
No established safe dose due to teratogenicity. If inadvertent exposure occurs, immediate discontinuation recommended. No dose adjustment is feasible given contraindication.
Nevanac (nepafenac) is a nonsteroidal anti-inflammatory drug (NSAID) ophthalmic suspension indicated for pain and inflammation associated with cataract surgery. Its prodrug formulation enhances corneal penetration, with active metabolite amfenac inhibiting COX-1 and COX-2. Administer one drop three times daily starting 1 day prior to surgery, continuing on day of surgery and for 2 weeks postoperatively. Avoid concurrent use of other NSAIDs or corticosteroids to mitigate risk of corneal adverse events. Monitor for signs of corneal epithelial breakdown, especially in patients with compromised corneal innervation (e.g., diabetes, prior ocular surgery).
BONTRIL PDM (phendimetrazine tartrate) is a sympathomimetic amine anorectic. Monitor blood pressure and heart rate due to potential increases. Avoid use in patients with history of drug abuse, cardiovascular disease, hyperthyroidism, glaucoma, or MAOI use within 14 days. Taper to avoid abrupt discontinuation. Not recommended for pediatric patients or those with hypertension.
Wash hands before and after instilling the drop.,Remove contact lenses before use and wait 10 minutes after administering before reinserting.,Do not touch the dropper tip to any surface to avoid contamination.,Apply one drop to the affected eye three times daily as directed, starting one day before cataract surgery.,Temporary blurred vision may occur; avoid driving or operating machinery until vision clears.,Notify your doctor if you experience eye pain, redness, sensitivity to light, or changes in vision.,Do not use other eye drops without consulting your doctor, especially other anti-inflammatory medications.,Store the bottle upright at room temperature, away from heat and light, and discard any unused suspension after the treatment period.
Take exactly as prescribed; do not exceed recommended dose.,Avoid driving or operating machinery until you know how this medication affects you.,Report chest pain, shortness of breath, or palpitations immediately.,Do not take with other stimulants or diet aids.,Inform your doctor if you become pregnant or plan to breastfeed.,Do not stop suddenly without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NEVANAC vs BONTRIL PDM, answered by our medical review team.
NEVANAC is a NSAID Ophthalmic that works by Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis and thereby suppressing ocular inflammation and pain.. BONTRIL PDM is a Sympathomimetic Anorectic that works by Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the release of norepinephrine and dopamine in the hypothalamus, reducing food intake. Topiramate is a sulfamate-substituted monosaccharide that enhances GABAergic activity and inhibits glutamatergic neurotransmission via AMPA/kainate receptors, leading to appetite suppression and increased energy expenditure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NEVANAC and BONTRIL PDM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NEVANAC is: One drop of 0.1% ophthalmic suspension instilled into the affected eye(s) three times daily.. The standard adult dose of BONTRIL PDM is: Oral: 5-10 mg once daily in the morning; maximum 20 mg/day. Oral disintegrating tablet: 5-10 mg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NEVANAC and BONTRIL PDM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NEVANAC is classified as Category C. Nepafenac is an NSAID. First trimester: limited human data, but NSAIDs as a class are associated with increased risk of spontaneous abortion and cardiac defects. Second trimester: . BONTRIL PDM is classified as Category C. First trimester: Category X. Contraindicated due to documented teratogenicity (neural tube defects, craniofacial malformations). Second/third trimester: Avoid due to risk of fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.